In our NSCLC cohort, the PRMT3 (low) IDO1 (low) group showed superior overall survival compared with the PRMT3 (high) IDO1 (high) group (Fig. 8E; Supplementary Table S10). This evidence concerns the gene PRMT3 and non-small cell lung carcinoma.